Oral squamous cell carcinoma (OSCC) is a widely recognized cancer that constitutes over 90 % of all oral cancer cases [1]. Thanks to advancements in cancer treatment, such as radiation, chemotherapy, and molecular target therapy, the 5-year relative survival rate for OSCC has more than doubled in the past 26 years. However, the exact cause and molecular process of OSCC have not been fully understood, and further investigation is necessary. CRISPR/Cas technology is seen as a groundbreaking tool in molecular biology, providing unparalleled accuracy in altering genes. Its use in conditions like OSCC shows excellent potential for advancing research and treatment development. OSCC, characterized by the growth of cancer cells in the lining of the mouth, presents challenges in its treatment and control. Traditional therapies like surgery, radiation, and chemotherapy often show limited success and may lead to severe side effects. The promise of CRISPR/Cas technology in tackling critical aspects of OSCC is apparent. In this correspondence, we discuss the recent advances in CRISPR technology in the OSCC milieu.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.prp.2025.155860 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modification of the splice acceptor in CD163 exon 7 of pigs is insufficient to confer resistance to PRRSV.
Vet Microbiol
March 2025
Department of Animal Science and Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE, United States. Electronic address:
CD163 is the primary receptor for PRRSV, and its SRCR5 domain, encoded by exon 7, is crucial for supporting PRRSV infection. Previous studies have used CRISPR/Cas9 technology to remove exon 7 from the host genome, and the edited pigs were completely resistant to PRRSV infection. In this study, we used CRISPR/Cas9 technology mimicking an adenine base editor (ABE) to edit the splice acceptor site of exon 7, rendering it nonfunctional.
View Article and Find Full Text PDFCharacterization of diverse Cas9 orthologs for genome and epigenome editing.
Proc Natl Acad Sci U S A
March 2025
Department of Biomedical Engineering, and Center for Advanced Genomic Technologies, Duke University, Durham, NC 27708.
CRISPR-Cas9 systems have revolutionized biotechnology, creating diverse new opportunities for biomedical research and therapeutic genome and epigenome editing. Despite the abundance of bacterial CRISPR-Cas9 systems, relatively few are effective in human cells, limiting the overall potential of CRISPR technology. To expand the CRISPR-Cas toolbox, we characterized a set of type II CRISPR-Cas9 systems from select bacterial genera and species encoding diverse Cas9s.
View Article and Find Full Text PDFPorous Silicon Nanoneedles Efficiently Deliver Adenine Base Editor to Correct a Recurrent Pathogenic COL7A1 Variant in Recessive Dystrophic Epidermolysis Bullosa.
Adv Mater
March 2025
Centre for Craniofacial and Regenerative Biology, King's College London, London, SE1 1UL, UK.
Base editing, a CRISPR-based genome editing technology, enables precise correction of single-nucleotide variants, promising resolutive treatment for monogenic genetic disorders like recessive dystrophic epidermolysis bullosa (RDEB). However, the application of base editors in cell manufacturing is hindered by inconsistent efficiency and high costs, contributed by suboptimal delivery methods. Nanoneedles have emerged as an effective delivery approach, enabling highly efficient, non-perturbing gene therapies both in vitro and in vivo.
View Article and Find Full Text PDFDetection of antimicrobial resistance via state-of-the-art technologies versus conventional methods.
Front Microbiol
February 2025
Department of Physiology, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia.
Antimicrobial resistance (AMR) is recognized as one of the foremost global health challenges, complicating the treatment of infectious diseases and contributing to increased morbidity and mortality rates. Traditionally, microbiological culture and susceptibility testing methods, such as disk diffusion and minimum inhibitory concentration (MIC) assays, have been employed to identify AMR bacteria. However, these conventional techniques are often labor intensive and time consuming and lack the requisite sensitivity for the early detection of resistance.
View Article and Find Full Text PDFPolysaccharide-Based Delivery Systems for CRISPR/Cas Gene Therapy: Overcoming Challenges and Advancing Pharmaceutical Solutions.
Curr Gene Ther
March 2025
Department of Pharmaceutical Sciences, Indira Gandhi University, Meerpur, Rewari - 123401, India.
The advent of CRISPR/Cas gene-editing technology has revolutionized molecular biology, offering unprecedented precision and potential in treating genetic disorders, cancers, and other complex diseases. However, for CRISPR/Cas to be truly effective in clinical settings, one of the most significant challenges lies in the delivery of the CRISPR components, including guide RNA (gRNA) and Cas protein, into specific cells or tissues. Safe, targeted, and efficient delivery remains a critical bottleneck.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!